-
1.发明申请Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders 审中-公开胰岛淀粉样多肽和胰岛淀粉样多肽激动剂治疗精神疾病和疾病公开(公告)号：US20090181890A1
公开(公告)日：2009-07-16
申请号：US12295259
申请日：2006-10-04
CPC分类号： A61K38/22 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
2.发明申请AMYLIN AND AMYLIN AGONISTS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS 失效用于治疗心理疾病和疾病的AMYLIN和AMYLIN激动剂公开(公告)号：US20110288028A1
公开(公告)日：2011-11-24
申请号：US13112290
申请日：2011-05-20
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
3.发明授权Amylin agonist for treating depression, anxiety disorder and schizophrenia 失效用于治疗抑郁症，焦虑障碍和精神分裂症的胰岛淀粉样多肽激动剂公开(公告)号：US07671023B2
公开(公告)日：2010-03-02
申请号：US11910206
申请日：2006-03-31
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
4.发明申请Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders 审中-公开胰岛淀粉样多肽和胰岛淀粉样多肽激动剂治疗精神疾病和疾病公开(公告)号：US20100125054A1
公开(公告)日：2010-05-20
申请号：US12641733
申请日：2009-12-18
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
公开(公告)号：US20130184213A1
公开(公告)日：2013-07-18
申请号：US13777149
申请日：2013-02-26
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
-
6.发明授权Amylin and amylin agonists for treating psychiatric diseases and disorders 失效胰岛淀粉样多肽和胰岛淀粉样多肽激动剂用于治疗精神疾病和病症公开(公告)号：US08389477B2
公开(公告)日：2013-03-05
申请号：US13112290
申请日：2011-05-20
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
7.发明申请Amylin and Amylin Agonists For Treating Psychiatric Diseases and Disorders 失效胰岛淀粉样多肽和胰岛淀粉样变性激素治疗精神疾病和疾病公开(公告)号：US20080287355A1
公开(公告)日：2008-11-20
申请号：US11910206
申请日：2006-03-31
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
公开(公告)号：US08263545B2
公开(公告)日：2012-09-11
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
9.发明授权公开(公告)号：US08497240B2
公开(公告)日：2013-07-30
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20130137631A1
公开(公告)日：2013-05-30
申请号：US13591677
申请日：2012-08-22
申请人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： C07K14/575 , C07K7/06
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.051 秒)
